[go: up one dir, main page]

CL2019002134A1 - Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas. - Google Patents

Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.

Info

Publication number
CL2019002134A1
CL2019002134A1 CL2019002134A CL2019002134A CL2019002134A1 CL 2019002134 A1 CL2019002134 A1 CL 2019002134A1 CL 2019002134 A CL2019002134 A CL 2019002134A CL 2019002134 A CL2019002134 A CL 2019002134A CL 2019002134 A1 CL2019002134 A1 CL 2019002134A1
Authority
CL
Chile
Prior art keywords
peptide
activation
therapeutic compositions
immunomodulatory
oncogenic mutation
Prior art date
Application number
CL2019002134A
Other languages
English (en)
Inventor
Eric Yi-Chun Huang
Sze-Wah Tse
Jared Iacovelli
Kristine Mckinney
Nicholas Valiante
Original Assignee
Modernatx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx Inc filed Critical Modernatx Inc
Publication of CL2019002134A1 publication Critical patent/CL2019002134A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA DESCRIPCIÓN PRESENTA COMPOSICIONES TERAPÉUTICAS INMUNOMODULADORAS DE UN ARNM QUE CODIFICA UN PÉPTIDO DE ACTIVACIÓN DE MUTACIONES ONCOGÉNICAS Y UN ARNM QUE CODIFICA UN POLIPÉPTIDO QUE POTENCIA RESPUESTAS INMUNITARIAS AL PÉPTIDO DE ACTIVACIÓN DE MUTACIONES ONCOGÉNICAS, POR EJEMPLO, UN ARNM QUE CODIFICA UN INMUNOPOTENCIADOR. LA DESCRIPCIÓN TAMBIÉN PRESENTA MÉTODOS PARA EL USO DE ESTAS, POR EJEMPLO, PARA ESTIMULAR LAS RESPUESTAS INMUNITARIAS CONTRA EL CÁNCER.
CL2019002134A 2017-02-01 2019-07-30 Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas. CL2019002134A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762453465P 2017-02-01 2017-02-01
US201762467063P 2017-03-03 2017-03-03
US201762490523P 2017-04-26 2017-04-26
US201762541571P 2017-08-04 2017-08-04

Publications (1)

Publication Number Publication Date
CL2019002134A1 true CL2019002134A1 (es) 2019-11-22

Family

ID=61244714

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002134A CL2019002134A1 (es) 2017-02-01 2019-07-30 Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.

Country Status (15)

Country Link
US (3) US20190351039A1 (es)
EP (1) EP3576780A1 (es)
JP (2) JP2020514321A (es)
KR (1) KR20190110612A (es)
CN (2) CN110430894A (es)
AU (1) AU2018214556A1 (es)
BR (1) BR112019015797A2 (es)
CA (1) CA3051252A1 (es)
CL (1) CL2019002134A1 (es)
CO (1) CO2019009234A2 (es)
EA (1) EA201991804A1 (es)
IL (1) IL268361A (es)
MX (2) MX2019009070A (es)
SG (1) SG11201906969PA (es)
WO (1) WO2018144775A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608798YA (en) 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
HK1256498A1 (zh) 2015-07-30 2019-09-27 Modernatx, Inc. 聚肽表位 rna
WO2017031232A1 (en) 2015-08-17 2017-02-23 Modernatx, Inc. Methods for preparing particles and related compositions
EP3350157B1 (en) 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
HRP20220872T1 (hr) 2015-10-22 2022-12-23 Modernatx, Inc. Cjepiva protiv respiratornih virusa
JP6925688B2 (ja) 2015-10-22 2021-08-25 モデルナティーエックス， インコーポレイテッド 水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
AU2016366978B2 (en) 2015-12-10 2022-07-28 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
JP7114465B2 (ja) 2015-12-22 2022-08-08 モデルナティエックス インコーポレイテッド 薬剤の細胞内送達のための化合物および組成物
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
AU2017326423B2 (en) 2016-09-14 2023-11-09 Modernatx, Inc. High purity RNA compositions and methods for preparation thereof
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CN110167587A (zh) 2016-11-11 2019-08-23 摩登纳特斯有限公司 流感疫苗
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
WO2018111967A1 (en) 2016-12-13 2018-06-21 Modernatx, Inc. Rna affinity purification
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
SMT202300097T1 (it) * 2017-03-15 2023-05-12 Modernatx Inc Composto e composizioni per il rilascio intracellulare di agenti terapeutici
MA52262A (fr) 2017-03-15 2020-02-19 Modernatx Inc Vaccin à large spectre contre le virus de la grippe
WO2018170256A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MA47790A (fr) 2017-03-17 2021-05-05 Modernatx Inc Vaccins à base d'arn contre des maladies zoonotiques
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
EP3638678B1 (en) 2017-06-14 2025-12-03 ModernaTX, Inc. Compounds and compositions for intracellular delivery of agents
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
JP7408098B2 (ja) 2017-08-18 2024-01-05 モデルナティエックス インコーポレイテッド Ｒｎａポリメラーゼバリアント
WO2019036683A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. ANALYTICAL METHODS BY HPLC
EP3668979A4 (en) 2017-08-18 2021-06-02 Modernatx, Inc. METHOD OF HPLC ANALYSIS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
CA3089117A1 (en) * 2018-01-30 2019-08-08 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells
MX2020013236A (es) 2018-06-06 2021-02-22 Massachusetts Inst Technology Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.
WO2020022898A2 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
IL321689A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Vaccines against breast cancer
CA3111836A1 (en) * 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
WO2020058239A1 (en) * 2018-09-18 2020-03-26 Universiteit Gent Therapeutic nanoparticles and methods of use thereof
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3852728B1 (en) 2018-09-20 2024-09-18 ModernaTX, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TW202039534A (zh) * 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
CN113795579A (zh) 2019-02-20 2021-12-14 摩登纳特斯有限公司 用于共转录加帽的rna聚合酶变体
CN113748124A (zh) * 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
EP3938507A4 (en) 2019-03-11 2023-02-22 ModernaTX, Inc. PROCEDURE FOR IN VITRO FED BATCH TRANSCRIPTION
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
IL310266B2 (en) 2019-05-22 2025-11-01 Massachusetts Inst Technology Circular rna compositions and methods
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
US12076438B2 (en) 2019-10-09 2024-09-03 Translate Bio, Inc. Compositions, methods and uses of messenger RNA
CA3157859A1 (en) * 2019-10-15 2021-04-22 Modernatx, Inc. Mrnas encoding immune modulating polypeptides and uses thereof
AU2020382614B2 (en) * 2019-11-12 2025-12-11 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
US20220409540A1 (en) * 2019-11-15 2022-12-29 Daiichi Sankyo Company, Limited Nucleic acid lipid particle vaccine encapsulating hpv mrna
CN115052635B (zh) 2019-12-04 2025-07-22 奥纳治疗公司 环状rna组合物和方法
KR102410556B1 (ko) * 2020-01-16 2022-06-20 아주대학교산학협력단 미토콘드리아 타겟팅용 펩타이드
WO2021155267A2 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
CN111440825A (zh) * 2020-04-07 2020-07-24 嘉晨西海(杭州)生物技术有限公司 一种脂质体载mRNA的方法
WO2021204179A1 (en) * 2020-04-09 2021-10-14 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
EP4133072A4 (en) * 2020-04-09 2024-11-06 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
EP3901260A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
KR20220109444A (ko) * 2020-04-24 2022-08-04 주식회사 제넥신 자궁경부암 치료방법
CA3178965A1 (en) 2020-05-15 2021-11-18 Christian COBAUGH Messenger rna encoding cas9 for use in genome-editing systems
WO2022035621A1 (en) * 2020-07-31 2022-02-17 Combined Therapeutics, Inc. Compositions and methods for improved vaccination
EP4194006A4 (en) * 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
AU2021360796A1 (en) * 2020-10-14 2023-06-08 RNAimmune, Inc. PAN-RAS mRNA CANCER VACCINES
CN116438306B (zh) 2020-10-20 2025-11-11 St制药株式会社 用于5′-加帽的rna合成的寡核苷酸
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CA3202227A1 (en) * 2020-11-20 2022-05-27 Think Therapeutics, Inc. Compositions and methods for optimized peptide vaccines
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
JP2024508347A (ja) * 2020-12-21 2024-02-27 ビーム セラピューティクス インク． エステル結合アセタールを含むナノ材料
EP4274607A1 (en) 2021-01-11 2023-11-15 ModernaTX, Inc. Seasonal rna influenza virus vaccines
CN116867799A (zh) * 2021-02-10 2023-10-10 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
EP4301405A4 (en) * 2021-03-05 2025-01-29 ModernaTX, Inc. ENTEROVIRAL VACCINES WITH VIRUS-LIKE PARTICLES (VLP)
JP2024511799A (ja) * 2021-03-26 2024-03-15 ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート ネオアンチゲンワクチンのための方法および化合物
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US20220364078A1 (en) 2021-05-14 2022-11-17 Crispr Therapeutics Ag Mrna large scale synthesis and purification
CN113264842B (zh) * 2021-07-21 2022-03-01 苏州科锐迈德生物医药科技有限公司 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN115703713B (zh) * 2021-08-13 2025-06-10 广州谷森制药有限公司 阳离子脂质化合物
JP2024534697A (ja) * 2021-09-14 2024-09-20 レナゲード セラピューティクス マネージメント インコーポレイテッド 非環状脂質及びその使用方法
WO2023061460A1 (zh) * 2021-10-15 2023-04-20 厦门赛诺邦格生物科技股份有限公司 含氮的阳离子脂质及其应用
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
WO2023122234A2 (en) * 2021-12-22 2023-06-29 Memorial Sloan-Kettering Cancer Center Cells expressing fas ligand and cflip polypeptides and uses thereof
WO2023125974A1 (zh) * 2021-12-31 2023-07-06 广州国家实验室 mRNA疫苗
US20250101078A1 (en) * 2022-01-21 2025-03-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
IL315096A (en) * 2022-03-16 2024-10-01 Boehringer Ingelheim Int Antigens, compounds containing KRAS, TPX2 or AURKA antigens and uses thereof
CN116655486A (zh) * 2022-05-19 2023-08-29 仁景(苏州)生物科技有限公司 长链烷基酯胺类化合物及其制备方法和在核酸递送方面的应用
CN115286674A (zh) * 2022-06-13 2022-11-04 湖北英纳氏生物科技有限公司 一种阳离子脂质体及其制备方法
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
CN115869332A (zh) * 2022-10-27 2023-03-31 北京新合睿恩生物医疗科技有限公司 递送至体内后在肝脏少表达的mRNA药物及其制备方法
WO2024102332A1 (en) * 2022-11-07 2024-05-16 Himv Llc Vaccine compositions comprising a neoantigen of kras
WO2024107827A1 (en) * 2022-11-16 2024-05-23 The Broad Institute, Inc. Therapeutic exploitation of sting channel activity
US20250332239A1 (en) * 2022-11-22 2025-10-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy
WO2024109866A1 (zh) 2022-11-24 2024-05-30 苏州艾博生物科技有限公司 提高蛋白表达量的utr分子
KR20240102892A (ko) * 2022-12-23 2024-07-03 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
WO2024151877A2 (en) 2023-01-11 2024-07-18 Engage Biologics Inc. Non-viral expression systems and methods of use thereof
WO2024199359A1 (zh) * 2023-03-28 2024-10-03 江苏瑞科生物技术股份有限公司 包含环二核苷酸分子的脂质体佐剂系统及其制备方法
WO2024211447A1 (en) * 2023-04-03 2024-10-10 Chrysalis Biotherapeutics Tp508 mrnas
CN117604031B (zh) * 2023-04-20 2025-05-09 龙岩学院 一种猫冠状病毒S蛋白mRNA的体外转录系统及其构建方法
CN119330848B (zh) * 2023-10-19 2025-07-08 仁景(苏州)生物科技有限公司 用于递送的脂质化合物及脂质纳米颗粒
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
KR20250148433A (ko) * 2024-03-29 2025-10-14 한미약품 주식회사 복수 kras 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8613481D0 (en) 1986-06-04 1986-07-09 Diatech Ltd Translation of mrna
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2284210B (en) 1993-11-26 1997-11-12 British Tech Group Translational enhancer DNA from a kinesin gene
US6027726A (en) 1994-09-30 2000-02-22 Inex Phamaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5824497A (en) 1995-02-10 1998-10-20 Mcmaster University High efficiency translation of mRNA molecules
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
US20060009633A9 (en) 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
EP1604688B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
CA2937159C (en) 2001-09-28 2017-11-28 Thomas Tuschl Microrna molecules
AU2002349784A1 (en) 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
GB0221574D0 (en) 2002-09-17 2002-10-23 Isis Innovation Treatments
CA2510238A1 (en) 2002-10-22 2004-05-06 Sanofi Pasteur Limited Cancer treatment using vaccine and high-dose cytokine
CA2503330A1 (en) 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
EP1581174B1 (en) 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
EP2505668A3 (en) 2006-01-05 2013-01-09 The Ohio State University Research Foundation MicroRNA-based methods for the diagnosis of colon, lung, and pancreatic cancer
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
US20100286232A1 (en) 2006-03-02 2010-11-11 The Ohio State University Microrna expression profile associated with pancreatic cancer
CA2647102A1 (en) * 2006-03-27 2007-11-22 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
JP5501766B2 (ja) 2006-11-01 2014-05-28 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 肝細胞癌における生存および転移を予測するためのマイクロｒｎａ発現サイン
WO2008073915A2 (en) 2006-12-08 2008-06-19 Asuragen, Inc. Micrornas differentially expressed in leukemia and uses thereof
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
WO2009029342A2 (en) 2007-07-13 2009-03-05 The Johns Hopkins University B7-dc variants
SI2660248T1 (sl) 2007-07-27 2015-10-30 Immatics Biotechnologies Gmbh Nova imunoterapija proti možganskim tumorjem
ES2573458T3 (es) 2007-09-14 2016-06-08 Vrije Universiteit Brussel Mejoramiento de la capacidad estimulatoria de las células T de las células que presentan antígeno humano y su uso en vacunación
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
WO2009070653A1 (en) 2007-11-30 2009-06-04 The Ohio State University Research Foundation Microrna expression profiling and targeting in peripheral blood in lung cancer
US20110165223A1 (en) 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
WO2009100430A2 (en) 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009108856A2 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami STING (STIMULATOR OF INTERFERON GENES) AS A REGULATOR OF BORROWING IMMUNE REACTIONS
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9074206B2 (en) 2008-11-13 2015-07-07 Fudan University Compositions and methods for micro-RNA expression profiling of colorectal cancer
EP2358902A1 (en) 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
EP2246433A1 (de) * 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
EP2427574A2 (en) 2009-05-08 2012-03-14 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
EP2440183B1 (en) 2009-06-10 2018-07-18 Arbutus Biopharma Corporation Improved lipid formulation
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
WO2011113030A2 (en) 2010-03-11 2011-09-15 H.Lee Moffitt Cancer Center & Research Institute Human cancer micro-rna expression profiles predictive of chemo-response
ES2788863T3 (es) 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
SI2611461T1 (sl) * 2010-08-31 2022-08-31 Glaxosmithkline Biologicals Sa Pegilirani liposomi za dostavo imunogen-kodirajoče RNA
SMT202300096T1 (it) * 2010-08-31 2023-05-12 Glaxosmithkline Biologicals Sa Liposomi piccoli per la somministrazione di rna codificante un immunogeno
EP3590949B1 (en) 2010-10-01 2022-05-18 ModernaTX, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
PL2633034T3 (pl) 2010-10-26 2018-05-30 Friedrich-Alexander-Universität Erlangen-Nürnberg KOMÓRKI DENDRYTYCZNE Z PODDANYM MANIPULACJI SZLAKIEM SYGNAŁOWYM NFkB
DK3202760T3 (da) 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
WO2012151212A1 (en) 2011-05-01 2012-11-08 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
CA3039234C (en) 2011-05-11 2023-03-28 Exosome Diagnostics, Inc. Nucleic acid extraction from heterogeneous biological materials
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
BR112013029490A2 (pt) * 2011-05-17 2019-09-24 Moderna Therapeutics Inc ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
RU2670745C9 (ru) 2011-05-24 2018-12-13 Бионтех Рна Фармасьютикалс Гмбх Индивидуализированные противоопухолевые вакцины
EP3998064A1 (en) 2011-06-08 2022-05-18 Translate Bio, Inc. Cleavable lipids
JP5965481B2 (ja) 2011-07-15 2016-08-03 レオ ファーマ アクティーゼルスカブ 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の診断用マイクロｒｎａプロファイリング
EP2751292A4 (en) 2011-09-01 2015-05-20 Allegro Diagnostics Corp METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES
JP6153526B2 (ja) 2011-09-06 2017-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ ポリペプチドワクチン
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
WO2013078199A2 (en) 2011-11-23 2013-05-30 Children's Medical Center Corporation Methods for enhanced in vivo delivery of synthetic, modified rnas
CA3165769A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
AU2012352180A1 (en) * 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013103659A1 (en) 2012-01-04 2013-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
CN103547683A (zh) * 2012-03-22 2014-01-29 耶鲁大学 Kras突变和肿瘤生物学
CN104411338A (zh) 2012-04-02 2015-03-11 现代治疗公司 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸
JP2015513912A (ja) 2012-04-02 2015-05-18 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． タンパク質の産生のための修飾ポリヌクレオチド
CA2907616A1 (en) 2012-04-30 2013-11-07 Glen N. Barber Modulating immune responses
KR20150006477A (ko) * 2012-05-09 2015-01-16 그래댈리스, 인코포레이티드 단일-뉴클레오타이드 ｋｒａｓ 돌연변이에 특이적인 이-기능성 짧은-헤어핀 ｒｎａ (ｂｉ-ｓｈｒｎａ)
KR20150022996A (ko) 2012-06-08 2015-03-04 아두로 바이오테크 암 면역요법을 위한 조성물 및 방법
AU2013291125A1 (en) * 2012-07-16 2015-01-22 Dicerna Pharmaceuticals, Inc. RNAi pharmaceutical composition capable of suppressing expression of KRAS gene
EP2892549A1 (en) 2012-09-04 2015-07-15 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
US10093701B2 (en) 2012-09-07 2018-10-09 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014093924A1 (en) 2012-12-13 2014-06-19 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
US20140200261A1 (en) 2013-01-17 2014-07-17 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
HK1220122A1 (zh) 2013-03-09 2017-04-28 Modernatx, Inc. Mrna的异源未转录区域
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
AU2014233424B2 (en) 2013-03-15 2017-03-16 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
US20160166676A1 (en) 2013-04-10 2016-06-16 Skau Aps Use of Immune Suppressive Peptides as Adjuvants
AU2014260015B2 (en) 2013-04-29 2019-11-14 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
ES2822584T3 (es) 2013-05-03 2021-05-04 Univ California Inducción de dinucleótidos cíclicos del interferón tipo I
WO2014189806A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
CA2904536A1 (en) 2013-05-18 2014-11-27 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
CN109394752A (zh) 2013-10-21 2019-03-01 德雷克塞尔大学 治疗慢性乙型肝炎病毒感染的sting激动剂的用途
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
DK3079715T3 (en) 2013-12-09 2018-09-17 Targovax Asa PEPTIDE MIXTURE
EP3094342A4 (en) 2014-01-15 2017-12-27 Nikolai Khodarev Anti-tumor therapy
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
EP3110401A4 (en) 2014-02-25 2017-10-25 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
EP3119893A1 (en) 2014-03-17 2017-01-25 Taplmmune Inc. Nucleic acid molecule vaccine compositions and uses thereof
SG11201608798YA (en) * 2014-04-23 2016-11-29 Modernatx Inc Nucleic acid vaccines
CA2944903A1 (en) * 2014-04-24 2015-10-29 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
AU2015257774B2 (en) 2014-05-06 2018-12-20 Targovax Solutions AS Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
EP3197490B1 (en) 2014-09-26 2023-06-21 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
EP4537906A3 (en) 2015-03-25 2025-08-20 The Regents of the University of Michigan Compositions and methods for delivery of biomacromolecule agents
SG10201907164SA (en) 2015-04-22 2019-09-27 Curevac Ag Rna containing composition for treatment of tumor diseases
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
US20180169159A1 (en) 2015-06-11 2018-06-21 University Of Miami Cancer treatment and diagnosis
HK1248714A1 (zh) * 2015-06-16 2018-10-19 Targovax Asa Ras蛋白的突变的片段
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
HK1256498A1 (zh) * 2015-07-30 2019-09-27 Modernatx, Inc. 聚肽表位 rna
CA2993429A1 (en) 2015-07-31 2017-02-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
EP3350157B1 (en) * 2015-09-17 2022-01-05 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2017062838A1 (en) 2015-10-07 2017-04-13 Nant Holdings Ip, Llc Activation of immune-related signalling pathways in cells via optofection
AU2016339924B2 (en) 2015-10-12 2020-01-02 Nantomics, Llc Compositions and methods for viral cancer neoepitopes
EP3365006A1 (en) 2015-10-19 2018-08-29 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
CN114404581A (zh) * 2015-10-22 2022-04-29 摩登纳特斯有限公司 癌症疫苗
PT3368507T (pt) 2015-10-28 2023-02-07 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
EP3393511A1 (en) 2015-12-21 2018-10-31 La Jolla Institute for Allergy and Immunology Leveraging immune memory from common childhood vaccines to fight disease
WO2017118702A1 (en) 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
WO2017152042A2 (en) 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
WO2017177204A1 (en) 2016-04-09 2017-10-12 La Jolla Institute For Allergy And Immunology Leveraging immune memory from common childhood vaccines to fight disease
CN109328070A (zh) 2016-05-04 2019-02-12 免疫疫苗技术有限公司 包含两亲化合物、新抗原和疏水载体的疫苗组合物及其使用方法
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
EP3471778A4 (en) 2016-06-20 2020-02-19 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ADMINISTERING BIOMACROMOLECULAR AGENTS
IL311369A (en) 2016-07-20 2024-05-01 BioNTech SE Selection of neoepitopes as disease-specific targets for therapy with increased efficacy
EP3503876A4 (en) 2016-08-23 2020-06-10 Jerome J. Schentag CHOLESTERYL ESTER VESICLES LOADING PEPTIDES, PROTEINS AND NUCLEIC ACIDS IN CHYLOMICRONS AND BODY CELLS
RU2765874C2 (ru) * 2016-10-26 2022-02-04 МОДЕРНАТиЭкс, ИНК. Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
MX2019005685A (es) 2016-11-30 2019-09-04 Advaxis Inc Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
AU2017375958A1 (en) 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
SG11201906969PA (en) 2017-02-01 2019-08-27 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides

Also Published As

Publication number Publication date
BR112019015797A2 (pt) 2020-03-17
MX2022011934A (es) 2022-10-20
US20190351039A1 (en) 2019-11-21
JP2023103250A (ja) 2023-07-26
EA201991804A1 (ru) 2020-02-07
US10881730B2 (en) 2021-01-05
MX2019009070A (es) 2019-10-30
WO2018144775A1 (en) 2018-08-09
SG11201906969PA (en) 2019-08-27
JP2020514321A (ja) 2020-05-21
KR20190110612A (ko) 2019-09-30
CN110430894A (zh) 2019-11-08
CO2019009234A2 (es) 2019-08-30
CN117224710A (zh) 2023-12-15
AU2018214556A1 (en) 2019-08-15
CA3051252A1 (en) 2018-08-09
IL268361A (en) 2019-09-26
US20210128721A1 (en) 2021-05-06
US20190175727A1 (en) 2019-06-13
EP3576780A1 (en) 2019-12-11

Similar Documents

Publication Publication Date Title
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
CL2021001744A1 (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324)
CL2021000149A1 (es) Composiciones anti-cd112r y métodos
CL2019002940A1 (es) Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer. (divisional solicitud 201801531)
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
CO2020015923A2 (es) Antagonista de gremlin-1 para la prevención y tratamiento del cáncer
MX2019012452A (es) Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9.
CL2019002942A1 (es) Nuevos péptidos y combinación para el uso en la inmunoterapia contra varios tipo de cáncer. (divisional solicitud 201801533)
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
AR108688A1 (es) Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
MX2022000263A (es) Nuevos antigenos y metodos contra el cancer.
MX2021015765A (es) Nuevos antigenos y metodos contra el cancer.
MX2021004453A (es) Nuevos antigenos y metodos contra el cancer.
CL2019000846A1 (es) Proteína terapéutica.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
EP3590954A3 (en) Koc1-derived peptide and vaccine including same
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
EP3848383A3 (en) Urlc10-derived peptide and vaccine containing same